Base de dados : MEDLINE
Pesquisa : B01.650.940.800.575.912.250.618.100.060.725 [Categoria DeCS]
Referências encontradas : 30 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 30 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28225220
[Au] Autor:Kakkos SK; Allaert FA
[Ad] Endereço:Department of Vascular Surgery, University Hospital of Patras, Patras, Greece - kakkos@upatras.gr.
[Ti] Título:Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort®, on improving individual venous symptoms and edema: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
[So] Source:Int Angiol;36(2):93-106, 2017 Apr.
[Is] ISSN:1827-1839
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Venoactive drugs (VADs) are considered an important component of the medical (conservative) treatment of chronic venous disorders (CVDs). However, the efficacy of certain VADs on one or more individual leg symptoms may have not been extensively studied to justify a high level or grade of recommendation in guidelines on CVD. The aim of the present systematic review and meta-analysis was to study the effectiveness of VADs containing Ruscus across the spectrum of defined venous symptoms. EVIDENCE ACQUISITION: On November 14 2016, a literature search of the databases MEDLINE and Scopus was performed, supplemented by hand searching, to identify randomized double-blind placebo-controlled trials on Ruscus extracts in patients with CVD. EVIDENCE SYNTHESIS: The main outcome measures were the effects of Ruscus on individual symptoms and leg edema, which were expressed as risk ratio (RR) or standardized mean difference (SMD) with 95% confidence interval (CI). Trial quality of evidence was graded using the GRADE system. We identified 10 trials, mostly with low risk of bias, on 719 patients. On qualitative analysis, Ruscus significantly improved seven defined leg symptoms, including pain, heaviness, fatigue, feeling of swelling, cramps, itching and paresthesia compared to placebo. On quantitative analysis, Ruscus compared with placebo, assessed as a categorical variable, reduced leg pain (RR=0.35, P=0.01, number needed to treat [NNT] 5, with no heterogeneity), heaviness (RR=0.26, P<0.00001, NNT=2.4, with a small amount of heterogeneity), feeling of swelling (RR=0.53, P<0.0001, NNT=4, with considerable heterogeneity, minimized after sensitivity analysis), paresthesia (RR=0.27, P<0.0001, NNT=1.8), global symptoms (RR=0.54, P<0.00001, NNT=4.3) and the total number of venous symptoms (RR 0.41, P=0.002). Similarly, Ruscus compared to placebo, assessed as a continuous variable reduced pain (SMD=-0.80, 95% CI: -1.21 to -0.39), heaviness (SMD=-1.23, 95% CI: -1.60 to -0.86), fatigue (SMD -1.16, 95% CI: -1.71 to -0.61), feeling of swelling (SMD=-2.27, 95% CI: -3.83 to -0.70), and paresthesia (SMD=-0.86, 95% CI: -1.51 to -0.21). Regarding objective assessments of leg edema, the use of Ruscus compared with placebo reduced ankle circumference (SMD=-0.74, 95% CI: -1.01 to -0.47) and leg or foot volume (SMD=-0.61, 95% CI: -0.91 to -0.31). The existing evidence, where sufficient, was mostly of high quality. CONCLUSIONS: Based on high quality evidence, Ruscus extracts are highly effective in reducing symptoms and edema of patients with CVD.
[Mh] Termos MeSH primário: Ácido Ascórbico/uso terapêutico
Edema/tratamento farmacológico
Fitoterapia/métodos
Extratos Vegetais/uso terapêutico
Ruscus/química
Doenças Vasculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Veias/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts); 0 (cyclo 3); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.23736/S0392-9590.17.03815-9


  2 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28124877
[Au] Autor:Jawien A; Bouskela E; Allaert FA; Nicolaïdes AN
[Ad] Endereço:Department of Vascular Surgery and Angiology, Collegium Medicum University of Nicolai Copernicus, Bydgoszcz, Poland - ajawien@ceti.com.pl.
[Ti] Título:The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease.
[So] Source:Int Angiol;36(1):31-41, 2017 Feb.
[Is] ISSN:1827-1839
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Despite continuous improvement in our knowledge and management of chronic venous disease (CVD), certain areas, such as the role of muscarinic receptors in the pathology and treatment of CVD, remain unexplored. The symposium "The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of CVD", held at the Annual Meeting of the European Venous Forum on 7-9 July 2016 in London, presented an update on the pathophysiology of CVD and highlighted how the combination of Ruscus extract, hesperidin methyl chalcone, and vitamin C (Ruscus/HMC/VitC; Cyclo 3® Fort), may counteract the deleterious processes underlying CVD. The data presented during this symposium are reported here. The pathophysiology of CVD is driven by a complex process involving numerous factors, with the two key players being venous hypertension and the inflammatory response. The cascade of reactions induced by disturbed venous flow, inflammation, and tissue alterations results in the early appearance of symptoms and progressive development of clinical signs of disease. Previous studies have shown that Ruscus extract acts at three levels: on the veins, capillaries and lymphatics, and has anti-inflammatory properties. A series of recent experiments has shed new light on the mechanism of action of the combination of Ruscus/HMC/VitC. The efficacy of Ruscus/HMC/VitC in CVD is supported by clinical studies, while two meta-analyses have confirmed a significant decrease of several symptoms and ankle circumference in response to treatment with this agent, leading to the conclusion that Ruscus/HMC/VitC deserves a Grade A rating.
[Mh] Termos MeSH primário: Ácido Ascórbico/uso terapêutico
Chalconas/uso terapêutico
Hesperidina/análogos & derivados
Extratos Vegetais/uso terapêutico
Ruscus/química
Doenças Vasculares/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Crônica
Congressos como Assunto
Quimioterapia Combinada
Hesperidina/uso terapêutico
Seres Humanos
Londres
Fitoterapia/métodos
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
Doenças Vasculares/fisiopatologia
Veias/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chalcones); 0 (Plant Extracts); 0 (cyclo 3); 4T2GVA922X (hesperidin methylchalcone); E750O06Y6O (Hesperidin); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170523
[Lr] Data última revisão:
170523
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170127
[St] Status:MEDLINE
[do] DOI:10.23736/S0392-9590.16.03788-3


  3 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27476482
[Au] Autor:Del Gaudio F; Festa C; Mozzicafreddo M; Vasaturo M; Casapullo A; De Marino S; Riccio R; Monti MC
[Ad] Endereço:Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084, Fisciano, Italy. mcmonti@unisa.it.
[Ti] Título:Biomolecular proteomics discloses ATP synthase as the main target of the natural glycoside deglucoruscin.
[So] Source:Mol Biosyst;12(10):3132-8, 2016 Oct 20.
[Is] ISSN:1742-2051
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Extracts of Ruscus aculeatus are a rich source of bioactive steroidal glycosides, such as ruscogenins which are reported to act against chronic venous disorders. Nowadays, several preparations of its roots, commonly used in traditional medicine, are on the market as food supplements for health care and maintenance. Although spirostanol deglucoruscin is one of the main metabolites in these extracts, literature reports about its pharmacological profile are scarce. In this paper, a multi-disciplinary approach, based on chemical proteomics, molecular modelling and bio-organic assays, has been used to disclose the whole interactome of deglucoruscin and the F0-F1 ATP synthase complex has been found as its main target.
[Mh] Termos MeSH primário: Produtos Biológicos/química
Glicosídeos/química
Proteômica
ATPases Translocadoras de Prótons/química
[Mh] Termos MeSH secundário: Produtos Biológicos/isolamento & purificação
Produtos Biológicos/farmacologia
Cromatografia de Afinidade
Relação Dose-Resposta a Droga
Ativação Enzimática/efeitos dos fármacos
Glicosídeos/isolamento & purificação
Glicosídeos/farmacologia
Seres Humanos
Espectrometria de Massas
Modelos Moleculares
Conformação Molecular
Estrutura Molecular
Extratos Vegetais/química
Extratos Vegetais/farmacologia
Proteômica/métodos
ATPases Translocadoras de Prótons/antagonistas & inibidores
ATPases Translocadoras de Prótons/metabolismo
Ruscus/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Glycosides); 0 (Plant Extracts); EC 3.6.3.14 (Proton-Translocating ATPases)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160802
[St] Status:MEDLINE
[do] DOI:10.1039/c6mb00460a


  4 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26928296
[Au] Autor:Allaert FA
[Ti] Título:Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: a comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease.
[So] Source:Int Angiol;35(2):111-6, 2016 Apr.
[Is] ISSN:1827-1839
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:This paper focuses on Ruscus aculeatus extract (Ruscus extract) and its combination with hesperidin methyl chalcone (HMC) and ascorbic acid (AA), which have been safely and effectively used in CVD treatment for more than 50 years in some European countries. It presents the effects of that drug on veins and on venous hypertension, its effect on microcirculation and on lymphatics demonstrated by preclinical studies and the clinical evidence issued from clinical trials supporting its use to relieve the symptoms of venous disease. In addition to its venoconstrictive effect on veins, its pharmacological action is on the microcirculation impairment caused by venous hypertension that is at the heart of the pathophysiological mechanism underlying venous disease.
[Mh] Termos MeSH primário: Ácido Ascórbico/uso terapêutico
Chalconas/uso terapêutico
Hesperidina/análogos & derivados
Extratos Vegetais/uso terapêutico
Ruscus/química
Doenças Vasculares/tratamento farmacológico
Veias/efeitos dos fármacos
[Mh] Termos MeSH secundário: Doença Crônica
Quimioterapia Combinada
Hesperidina/uso terapêutico
Seres Humanos
Fitoterapia
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chalcones); 0 (Plant Extracts); 4T2GVA922X (hesperidin methylchalcone); E750O06Y6O (Hesperidin); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170123
[Lr] Data última revisão:
170123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160302
[St] Status:MEDLINE


  5 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26563681
[Au] Autor:Calapai G; Minciullo PL; Miroddi M; Chinou I; Gangemi S; Schmidt RJ
[Ad] Endereço:Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
[Ti] Título:Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products - Part 3: Mentha × piperita - Solanum dulcamara.
[So] Source:Contact Dermatitis;74(3):131-44, 2016 Mar.
[Is] ISSN:1600-0536
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This review focuses on contact dermatitis as an adverse effect of a selection of topically used herbal medicinal products for which the European Medicines Agency has completed an evaluation up to the end of November 2013 and for which a Community herbal monograph - now (since 2015)(†) called a European Union herbal monograph - has been produced. Part 3: Mentha × piperita L.-Solanum dulcamara L.
[Mh] Termos MeSH primário: Dermatite de Contato/etiologia
Mentha piperita/efeitos adversos
Fitoterapia/efeitos adversos
Preparações de Plantas/efeitos adversos
Rosmarinus/efeitos adversos
Salvia officinalis/efeitos adversos
[Mh] Termos MeSH secundário: Europa (Continente)
Seres Humanos
Oenothera biennis/efeitos adversos
Pimpinella/efeitos adversos
Quercus/efeitos adversos
Ruscus/efeitos adversos
Solanum/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plant Preparations)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151114
[St] Status:MEDLINE
[do] DOI:10.1111/cod.12483


  6 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26406967
[Au] Autor:Chudek J; Mikosinski J; Kobielski A; Hering A; Aleksiejew-Kleszczynski T; Uminski J; Zubilewicz T; Kobusiewicz W; Ilzecki M; Wojtak A; Stec J; Urbanek T
[Ad] Endereço:Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland - chj@poczta.fm.
[Ti] Título:Patients' satisfaction with therapy methods of advanced chronic venous disease.
[So] Source:Int Angiol;35(1):98-107, 2016 Feb.
[Is] ISSN:1827-1839
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To assess patients' satisfaction from the therapy of advanced chronic venous disorders (CVD) in everyday clinical practice in Poland, and to compare the efficacy of various venoactive drugs (VADs) in venous ulcers healing process. METHODS: Seven hundred and eighty unselected adult patients with active (N.=441) or healed (N.=339) venous ulcers participated in the non-interventional observational 6-week study. RESULTS: Compression therapy and VADs were utilized by 81.5% and 89.2% of patients respectively: 31.2% of all patients underwent surgical procedures for vein incompetence, 61.3% were satisfied with surgical methods, 43% with compression therapy, and 32.6% with VADs ­ with highest rate of satisfied patients in the group taking Ruscus aculeatus and HMC and ascorbic acid (51.4%). Of 377 patients with active venous ulcers smaller than 200 cm2, adherent to VADs, 18.0% have been cured, and 66.6% have improved during 6-week period of observation. Multiple logistic regression analysis revealed that the compression therapy (OR=2.74), the size of ulcer ≤10 cm2 (OR=2.70) were increasing the change of ulcer healing. No VADs was better than another in the healing process. CONCLUSION: 1) Compression therapy and VADs are highly utilized by patients with advanced CVD. 2) Patients are more satisfied with surgical than conservative treatment of advanced CVD. 3) More than half of the patients with the advanced stage CVD taking Ruscus aculeatus and HMC and ascorbic acid is satisfied with the obtained improvement. 4) Ruscus aculeatus and HMC and ascorbic acid is similarly effective as other frequently used VADs in venous ulcer healing. 5) Ruscus aculeatus and HMC and ascorbic acid exerting effects on veins, capillaries and lymphatic vessels may explain the positive results observed in this study.
[Mh] Termos MeSH primário: Ácido Ascórbico/uso terapêutico
Chalconas/uso terapêutico
Hesperidina/análogos & derivados
Satisfação do Paciente
Fitoterapia
Extratos Vegetais/uso terapêutico
Ruscus
Úlcera Varicosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Doença Crônica
Feminino
Hesperidina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Cicatrização
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Chalcones); 0 (Plant Extracts); 4T2GVA922X (hesperidin methylchalcone); E750O06Y6O (Hesperidin); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150926
[St] Status:MEDLINE


  7 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23849361
[Au] Autor:Sadarmin PP; Timperley J
[Ad] Endereço:Department of Cardiology, Northampton General Hospital, UK.
[Ti] Título:An unusual case of Butcher's Broom precipitating diabetic ketoacidosis.
[So] Source:J Emerg Med;45(3):e63-5, 2013 Sep.
[Is] ISSN:0736-4679
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Herbal medicines are readily available and commonly perceived to be relatively harmless. Butcher's Broom is used in various medicinal preparations and contains substances having α-adrenergic-stimulating properties. OBJECTIVE: Our aim was to report a case of toxicity associated with Butcher's Broom in a diabetic patient. CASE REPORT: A 39-year-old woman developed diabetic ketoacidosis 5 days after beginning therapy with Butcher's Broom for mild ankle swelling. Her diabetic ketoacidosis was complicated by hyperkalemia and acidosis with a pH of 7.02. After management with intravenous fluid, insulin, and calcium gluconate, her condition stabilized and she was discharged several days later. CONCLUSIONS: This case represents a small but potentially serious public health concern in a diabetic woman taking Butcher's Broom.
[Mh] Termos MeSH primário: Complicações do Diabetes/induzido quimicamente
Edema/tratamento farmacológico
Cetose/induzido quimicamente
Fitoterapia
Ruscus/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Feminino
Hidratação
Seres Humanos
Hiperpotassemia/induzido quimicamente
Hiperpotassemia/tratamento farmacológico
Cetose/tratamento farmacológico
Preparações de Plantas/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Preparations)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:130902
[Lr] Data última revisão:
130902
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130716
[St] Status:MEDLINE


  8 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23499166
[Au] Autor:Barbic M; Willer EA; Rothenhöfer M; Heilmann J; Fürst R; Jürgenliemk G
[Ad] Endereço:University of Regensburg, Pharmaceutical Biology, Universitätsstr. 31, 93053 Regensburg, Germany.
[Ti] Título:Spirostanol saponins and esculin from Rusci rhizoma reduce the thrombin-induced hyperpermeability of endothelial cells.
[So] Source:Phytochemistry;90:106-13, 2013 Jun.
[Is] ISSN:1873-3700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Rusci rhizoma extracts are traditionally used against chronic venous disorders (CVD). To determine the effect of its secondary plant metabolites on the endothelium, phenolic compounds and saponins from Butcher's broom were isolated from a methanolic extract, and their activity on the thrombin-induced hyperpermeability of human microvascular endothelial cells (HMEC-1) was investigated in vitro. In addition to the six known spirostanol saponins deglucoruscin (5), 22-O-methyl-deglucoruscoside (6), deglucoruscoside (7), ruscin (8), ruscogenin-1-O-(α-l-rhamnopyranosyl-(1→2)-ß-d-galactopyranoside (9) and 1-O-sulpho-ruscogenin (10), three new spirostanol derivatives were isolated and identified: 3'-O-acetyl-4'-O-sulphodeglucoruscin (1), 4'-O-(2-hydroxy-3-methylpentanoyl)-deglucoruscin (2) and 4'-O-acetyl-deglucoruscin (3). Furthermore, the coumarin esculin (4), which is also prominently present in other medicinal plants used in the treatment of CVD, was isolated for the first time from Rusci rhizoma. Five of the isolated steroid derivatives (2, 5, 8, 9 and 10) and esculin (4) were tested for their ability to reduce the thrombin-induced hyperpermeability of endothelial cells in vitro, and the results were compared to those of the aglycone neoruscogenin (11). The latter compound showed a slight but concentration-dependent reduction in hyperpermeability to 71.8% at 100µM. The highest activities were observed for the spirostanol saponins 5 and 8 and for esculin (4) at 10µM, and these compounds resulted in a reduction of the thrombin-induced hyperpermeability to 41.9%, 42.6% and 53.3%, respectively. For 2, 5 and 8, the highest concentration tested (100µM) resulted in a drastic increase of the thrombin effect. The effect of esculin observed at a concentration of 10µM was diminished at 100µM. These in vitro data provide insight into the pharmacological mechanism by which the genuine spirostanol saponins and esculin can contribute to the efficacy of Butcher's broom against chronic venous disorders.
[Mh] Termos MeSH primário: Células Endoteliais/efeitos dos fármacos
Esculina/farmacologia
Ruscus/química
Saponinas/farmacologia
Espirostanos/farmacologia
Trombina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Células Cultivadas
Relação Dose-Resposta a Droga
Células Endoteliais/metabolismo
Esculina/química
Esculina/isolamento & purificação
Seres Humanos
Estrutura Molecular
Permeabilidade/efeitos dos fármacos
Saponinas/química
Saponinas/isolamento & purificação
Espirostanos/química
Espirostanos/isolamento & purificação
Relação Estrutura-Atividade
Trombina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Saponins); 0 (Spirostans); 1Y1L18LQAF (Esculin); EC 3.4.21.5 (Thrombin)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:130422
[Lr] Data última revisão:
130422
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130319
[St] Status:MEDLINE


  9 / 30 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23183890
[Au] Autor:De Marino S; Festa C; Zollo F; Iorizzi M
[Ad] Endereço:Dipartimento di Chimica delle Sostanze Naturali, Università degli Studi di Napoli Federico II, Via D. Montesano 49, I-80131 Napoli, Italy. sidemari@unina.it
[Ti] Título:Novel steroidal components from the underground parts of Ruscus aculeatus L.
[So] Source:Molecules;17(12):14002-14, 2012 Nov 26.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Two new furostanol saponins 1–2 and three new sulphated glycosides 3a,b and 4 were isolated from the underground parts of Ruscus aculeatus L., along with four known furostanol and one spirostanol saponins 5–9 and three free sterols. All of the structures have been elucidated on the basis of spectroscopic data 1D and 2D NMR experiments, MS spectra and GC analyses.
[Mh] Termos MeSH primário: Saponinas
Espirostanos
Esteroides
Esteróis
[Mh] Termos MeSH secundário: Espectroscopia de Ressonância Magnética
Estrutura Molecular
Raízes de Plantas/química
Ruscus/química
Saponinas/química
Saponinas/isolamento & purificação
Espirostanos/química
Espirostanos/isolamento & purificação
Esteroides/química
Esteroides/isolamento & purificação
Esteróis/química
Esteróis/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Saponins); 0 (Spirostans); 0 (Steroids); 0 (Sterols); 0 (furostanol saponin I)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:121127
[Lr] Data última revisão:
121127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121128
[St] Status:MEDLINE
[do] DOI:10.3390/molecules171214002


  10 / 30 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22700226
[Au] Autor:Barbic M; Schmidt TJ; Jürgenliemk G
[Ad] Endereço:Institute of Pharmacy, Pharmaceutical Biology, University of Regensburg, Universitätsstr. 31, D-93053 Regensburg.
[Ti] Título:Novel phenyl-1-benzoxepinols from butcher's broom (Rusci rhizoma).
[So] Source:Chem Biodivers;9(6):1077-83, 2012 Jun.
[Is] ISSN:1612-1880
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Two novel compounds, (3S)-2,3-dihydro-3-(4-hydroxyphenyl)-1-benzoxepin-8-ol (ruscozepine A) and (3S)-2,3-dihydro-3-(4-hydroxyphenyl)-8-methoxy-1-benzoxepin-7-ol (ruscozepine B) were isolated from butcher's broom (Rusci rhizoma) together with a biosynthetically possible phenylethanoid precursor, hydroxytyrosol. The structures were elucidated by spectroscopic methods such as 1D- and 2D-NMR (COSY, HSQC, HMBC, ROESY), and HR-EI-MS experiments. The absolute configuration of the ruscozepines was determined by electronic circular dichroism.
[Mh] Termos MeSH primário: Benzoxepinas/química
Ruscus/química
[Mh] Termos MeSH secundário: Benzoxepinas/isolamento & purificação
Dicroísmo Circular
Espectroscopia de Ressonância Magnética
Conformação Molecular
Rizoma/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 ((3S)-2,3-dihydro-3-(4-hydroxyphenyl)-1-benzoxepin-8-ol); 0 ((3S)-2,3-dihydro-3-(4-hydroxyphenyl)-8-methoxy-1-benzoxepin-7-ol); 0 (Benzoxepins)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:120615
[Lr] Data última revisão:
120615
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120616
[St] Status:MEDLINE
[do] DOI:10.1002/cbdv.201100158



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde